메뉴 건너뛰기




Volumn 124, Issue 10, 2014, Pages 4564-4576

Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; AKB 9778; ANGIOPOIETIN RECEPTOR; MESSENGER RNA; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL PROTEIN TYROSINE PHOSPHATASE; AKB-9778; ANILINE DERIVATIVE; OXYGEN; RECEPTOR LIKE PROTEIN TYROSINE PHOSPHATASE; SULFONIC ACID DERIVATIVE; TEK PROTEIN, MOUSE; VASCULOTROPIN A;

EID: 84907494958     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI74527     Document Type: Article
Times cited : (178)

References (64)
  • 1
    • 0037699954 scopus 로고    scopus 로고
    • The biology of VEGF and its receptors
    • Ferrara N, Gerber H-P, Le Couter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669-676.
    • (2003) Nat Med. , vol.9 , Issue.6 , pp. 669-676
    • Ferrara, N.1    Gerber, H.-P.2    Le Couter, J.3
  • 2
    • 4143136640 scopus 로고    scopus 로고
    • Vascular endothelial growth factor: Basic science and clinical progress
    • Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25(4):581-611.
    • (2004) Endocr Rev. , vol.25 , Issue.4 , pp. 581-611
    • Ferrara, N.1
  • 3
    • 33749445317 scopus 로고    scopus 로고
    • Ranibizumab for neovascular age-related macular degeneration
    • Rosenfeld PJ, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431.
    • (2006) N Engl J Med. , vol.355 , Issue.14 , pp. 1419-1431
    • Rosenfeld, P.J.1
  • 4
    • 33845191304 scopus 로고    scopus 로고
    • Vascular endothelial growth factor is a critical stimulus for diabetic macular edema
    • Nguyen QD, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol. 2006;142(6):961-969.
    • (2006) Am J Ophthalmol. , vol.142 , Issue.6 , pp. 961-969
    • Nguyen, Q.D.1
  • 5
    • 41149085598 scopus 로고    scopus 로고
    • Ranibizumab for macular edema due to retinal vein occlusions; implication of VEGF as a critical stimulator
    • Campochiaro PA, et al. Ranibizumab for macular edema due to retinal vein occlusions; implication of VEGF as a critical stimulator. Mol Ther. 2008;16(4):791-799.
    • (2008) Mol Ther. , vol.16 , Issue.4 , pp. 791-799
    • Campochiaro, P.A.1
  • 6
    • 77952891051 scopus 로고    scopus 로고
    • Ranibizumab for macular edema following branch retinal vein occlusion: 6-month primary endpoint results of a phase III study
    • Campochiaro PA, et al. Ranibizumab for macular edema following branch retinal vein occlusion: 6-month primary endpoint results of a phase III study. Ophthalmology. 2010;117(6):1102-1112.
    • (2010) Ophthalmology , vol.117 , Issue.6 , pp. 1102-1112
    • Campochiaro, P.A.1
  • 7
    • 77952889477 scopus 로고    scopus 로고
    • Efficacy and safety of ranibizumab in the treatment of macular edema secondary to central retinal vein occlusion:6-month results of the phase III CRUISE study
    • Brown DM, et al. Efficacy and safety of ranibizumab in the treatment of macular edema secondary to central retinal vein occlusion:6-month results of the phase III CRUISE study. Ophthalmology. 2010;117(6):1124-1133.
    • (2010) Ophthalmology , vol.117 , Issue.6 , pp. 1124-1133
    • Brown, D.M.1
  • 8
    • 84863401792 scopus 로고    scopus 로고
    • Ranibizumab for diabetic macular edema: Results from 2 phase III randomized trials: RISE and RIDE
    • Nguyen QD, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789-801.
    • (2012) Ophthalmology , vol.119 , Issue.4 , pp. 789-801
    • Nguyen, Q.D.1
  • 9
    • 84862817252 scopus 로고    scopus 로고
    • Ranibizumab for macular edema due to retinal vein occlusions: Long term follow-up in the HORIZON trial
    • Heier JS, et al. Ranibizumab for macular edema due to retinal vein occlusions: long term follow-up in the HORIZON trial. Ophthalmology. 2012;119(4):802-809.
    • (2012) Ophthalmology , vol.119 , Issue.4 , pp. 802-809
    • Heier, J.S.1
  • 10
    • 78049293726 scopus 로고    scopus 로고
    • Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study
    • Nguyen QD, et al. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2010;117(11):2146-2151.
    • (2010) Ophthalmology , vol.117 , Issue.11 , pp. 2146-2151
    • Nguyen, Q.D.1
  • 11
    • 84891631064 scopus 로고    scopus 로고
    • Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: The RETAIN study
    • Campochiaro PA, et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology. 2014;121(1):209-219.
    • (2014) Ophthalmology , vol.121 , Issue.1 , pp. 209-219
    • Campochiaro, P.A.1
  • 12
    • 15144358851 scopus 로고    scopus 로고
    • Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis
    • Maisonpierre PC, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997;277(5322):55-60.
    • (1997) Science , vol.277 , Issue.5322 , pp. 55-60
    • Maisonpierre, P.C.1
  • 13
    • 0033882191 scopus 로고    scopus 로고
    • Angiopoietin 2 expression in the retina: Upregulation during physiologic and pathologic neovascularization
    • Hackett SF, et al. Angiopoietin 2 expression in the retina: upregulation during physiologic and pathologic neovascularization. J Cell Physiol. 2000;184(3):275-284.
    • (2000) J Cell Physiol. , vol.184 , Issue.3 , pp. 275-284
    • Hackett, S.F.1
  • 15
    • 18644382318 scopus 로고    scopus 로고
    • Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1
    • Gale NW, et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Dev Cell. 2002;3(3):411-423.
    • (2002) Dev Cell. , vol.3 , Issue.3 , pp. 411-423
    • Gale, N.W.1
  • 16
    • 2342592123 scopus 로고    scopus 로고
    • Intraocular gutless adenoviral vectored VEGF stimulates anterior segment but not retinal neovascularization
    • Oshima Y, et al. Intraocular gutless adenoviral vectored VEGF stimulates anterior segment but not retinal neovascularization. J Cell Physiol. 2004;199(3):399-411.
    • (2004) J Cell Physiol. , vol.199 , Issue.3 , pp. 399-411
    • Oshima, Y.1
  • 17
    • 20444437236 scopus 로고    scopus 로고
    • Different effects of angiopoietin 2 in different vascular beds in the eye; new vessels are most sensitive
    • Oshima Y, et al. Different effects of angiopoietin 2 in different vascular beds in the eye; new vessels are most sensitive. FASEB J. 2005;19(8):963-965.
    • (2005) FASEB J. , vol.19 , Issue.8 , pp. 963-965
    • Oshima, Y.1
  • 18
    • 0030480322 scopus 로고    scopus 로고
    • Requisite role of Angiopoietin-1, a ligand for the Tie2 receptor, during embryonic angiogenesis
    • Suri C, et al. Requisite role of Angiopoietin-1, a ligand for the Tie2 receptor, during embryonic angiogenesis. Cell. 1996;87(7):1171-1180.
    • (1996) Cell , vol.87 , Issue.7 , pp. 1171-1180
    • Suri, C.1
  • 19
    • 2642557374 scopus 로고    scopus 로고
    • Angiopoietin 1 inhibits ocular neovascularization and breakdown of the blood-retinal barrier
    • Nambu H, et al. Angiopoietin 1 inhibits ocular neovascularization and breakdown of the blood-retinal barrier. Gene Ther. 2004;11(10):865-873.
    • (2004) Gene Ther. , vol.11 , Issue.10 , pp. 865-873
    • Nambu, H.1
  • 20
    • 20144374351 scopus 로고    scopus 로고
    • Angiopoietin 1 prevents retinal detachment in an aggressive model of proliferative retinopathy, but has no effect on established neovascularization
    • Nambu H, Umeda N, Kachi S, Oshima Y, Nambu R, Campochiaro PA. Angiopoietin 1 prevents retinal detachment in an aggressive model of proliferative retinopathy, but has no effect on established neovascularization. J Cell Physiol. 2005;204(1):227-235.
    • (2005) J Cell Physiol. , vol.204 , Issue.1 , pp. 227-235
    • Nambu, H.1    Umeda, N.2    Kachi, S.3    Oshima, Y.4    Nambu, R.5    Campochiaro, P.A.6
  • 21
    • 0025146562 scopus 로고
    • Structural diversity and evolution of human receptorlike protein tyrosine phosphatases
    • Krueger NX, Streuli M, Saito H. Structural diversity and evolution of human receptorlike protein tyrosine phosphatases. EMBO J. 1990;9(10):3241-3252.
    • (1990) EMBO J. , vol.9 , Issue.10 , pp. 3241-3252
    • Krueger, N.X.1    Streuli, M.2    Saito, H.3
  • 22
    • 0033592739 scopus 로고    scopus 로고
    • Functional interaction of vascular endothelial-protein-tyrosine phosphatase with the angiopoietin receptor Tie-2
    • Fachinger G, Deutsch U, Risau W. Functional interaction of vascular endothelial-protein-tyrosine phosphatase with the angiopoietin receptor Tie-2. Oncogene. 1999;18(43):5948-5953.
    • (1999) Oncogene. , vol.18 , Issue.43 , pp. 5948-5953
    • Fachinger, G.1    Deutsch, U.2    Risau, W.3
  • 23
    • 33745107561 scopus 로고    scopus 로고
    • Vascular endothelial cell-specific phosphotyrosine phosphatase (VE-PTP) activity is required for blood vessel development
    • Baumer S, et al. Vascular endothelial cell-specific phosphotyrosine phosphatase (VE-PTP) activity is required for blood vessel development. Blood. 2006;107(12):4754-4762.
    • (2006) Blood , vol.107 , Issue.12 , pp. 4754-4762
    • Baumer, S.1
  • 24
    • 33847636046 scopus 로고    scopus 로고
    • Vascular endothelial tyrosine phosphatase (VE-PTP)-null mice undergo vasculogenesis but die embryonically because of defects in angiogenesis
    • Dominguez MG, et al. Vascular endothelial tyrosine phosphatase (VE-PTP)-null mice undergo vasculogenesis but die embryonically because of defects in angiogenesis. Proc Natl Acad Sci U S A. 2007;104(9):3243-3248.
    • (2007) Proc Natl Acad Sci U S A , vol.104 , Issue.9 , pp. 3243-3248
    • Dominguez, M.G.1
  • 26
    • 66149094158 scopus 로고    scopus 로고
    • VE-PTP control blood vessel development by balancing Tie-2 activity
    • Winderlich M, et al. VE-PTP control blood vessel development by balancing Tie-2 activity. J Cell Biol. 2009;185(4):657-671.
    • (2009) J Cell Biol. , vol.185 , Issue.4 , pp. 657-671
    • Winderlich, M.1
  • 27
    • 0027982899 scopus 로고
    • Oxygen-induced retinopathy in the mouse
    • Smith L E H, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35(1):101-111.
    • (1994) Invest Ophthalmol Vis Sci. , vol.35 , Issue.1 , pp. 101-111
    • Smith, L.E.H.1
  • 28
    • 0034791933 scopus 로고    scopus 로고
    • Retinal angiomatous proliferation in age-related macular degeneration
    • Yannuzzi LA, et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina. 2001;21(5):416-434.
    • (2001) Retina. , vol.21 , Issue.5 , pp. 416-434
    • Yannuzzi, L.A.1
  • 29
    • 0031768434 scopus 로고    scopus 로고
    • Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model
    • Tobe T, et al. Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am J Pathol. 1998;153(5):1641-1646.
    • (1998) Am J Pathol. , vol.153 , Issue.5 , pp. 1641-1646
    • Tobe, T.1
  • 30
    • 0030844479 scopus 로고    scopus 로고
    • Transgenic mice with increased expression of vascular endothelial growth factor in the retina: A new model of intraretinal and subretinal neovascularization
    • Okamoto N, et al. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol. 1997;151(1):281-291.
    • (1997) Am J Pathol. , vol.151 , Issue.1 , pp. 281-291
    • Okamoto, N.1
  • 31
    • 0031975156 scopus 로고    scopus 로고
    • Evolution of neovascularization in mice with overexpression of vascular endothelial growth factor in photoreceptors
    • Tobe T, et al. Evolution of neovascularization in mice with overexpression of vascular endothelial growth factor in photoreceptors. Invest Ophthalmol Vis Sci. 1998;39(1):180-188.
    • (1998) Invest Ophthalmol Vis Sci. , vol.39 , Issue.1 , pp. 180-188
    • Tobe, T.1
  • 32
    • 0037401890 scopus 로고    scopus 로고
    • VEGF-TRAPR1R2 suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier
    • Saishin Y, et al. VEGF-TRAPR1R2 suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol. 2003;195(2):241-248.
    • (2003) J Cell Physiol. , vol.195 , Issue.2 , pp. 241-248
    • Saishin, Y.1
  • 33
    • 79957990661 scopus 로고    scopus 로고
    • The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as needed after 12-week fixed dosing
    • Heier JS, et al. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as needed after 12-week fixed dosing. Ophthalmology. 2011;118(6):1098-1106.
    • (2011) Ophthalmology , vol.118 , Issue.6 , pp. 1098-1106
    • Heier, J.S.1
  • 34
    • 32044449378 scopus 로고    scopus 로고
    • 1, 2, 3, 4-Tetrahydroisoquinolinyl sulfamic acids as phsophatase PTP1B inhibitors
    • Klopfenstein SR, et al. 1, 2, 3, 4-Tetrahydroisoquinolinyl sulfamic acids as phsophatase PTP1B inhibitors. Bioorg Med Chem Lett. 2006;16(6):1574-1578.
    • (2006) Bioorg Med Chem Lett. , vol.16 , Issue.6 , pp. 1574-1578
    • Klopfenstein, S.R.1
  • 35
    • 33845479013 scopus 로고    scopus 로고
    • Engineering the catalytic domain of human protein tyrosine phosphatase β for structure-based drug discovery
    • Evdokimov AG, et al. Engineering the catalytic domain of human protein tyrosine phosphatase β for structure-based drug discovery. Acta Crystallogr D Biol Crystallogr. 2006;62(pt 12):1435-1445.
    • (2006) Acta Crystallogr D Biol Crystallogr. , vol.62 , pp. 1435-1445
    • Evdokimov, A.G.1
  • 36
    • 33745953734 scopus 로고    scopus 로고
    • Design and synthesis of potent, non-peptidic inhibiors of HPTPβ
    • Amarasinghe K K D, et al. Design and synthesis of potent, non-peptidic inhibiors of HPTPβ. Bioorg Med Chem Lett. 2006;16(16):4252-4256.
    • (2006) Bioorg Med Chem Lett. , vol.16 , Issue.16 , pp. 4252-4256
    • Amarasinghe, K.K.D.1
  • 37
    • 0033601357 scopus 로고    scopus 로고
    • Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1
    • Thurston G, et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science. 1999;286(5449):2511-2515.
    • (1999) Science , vol.286 , Issue.5449 , pp. 2511-2515
    • Thurston, G.1
  • 38
    • 0024551654 scopus 로고
    • Immunohistochemical localization of blood-retinal barrier breakdown in human diabetics
    • Vinores SA, Gadegbeku C, Campochiaro PA, Green WR. Immunohistochemical localization of blood-retinal barrier breakdown in human diabetics. Am J Pathol. 1989;134(2):231-235.
    • (1989) Am J Pathol. , vol.134 , Issue.2 , pp. 231-235
    • Vinores, S.A.1    Gadegbeku, C.2    Campochiaro, P.A.3    Green, W.R.4
  • 39
    • 0025301320 scopus 로고
    • Localization of blood-retinal barrier breakdown in human pathologic specimens by immunohistochemical staining for albumin
    • Vinores SA, Campochiaro PA, Lee A, McGehee R, Gadegbeku C, Green WR. Localization of blood-retinal barrier breakdown in human pathologic specimens by immunohistochemical staining for albumin. Lab Invest. 1990;62(6):742-750.
    • (1990) Lab Invest. , vol.62 , Issue.6 , pp. 742-750
    • Vinores, S.A.1    Campochiaro, P.A.2    Lee, A.3    McGehee, R.4    Gadegbeku, C.5    Green, W.R.6
  • 40
    • 0037401530 scopus 로고    scopus 로고
    • Inhibition of protein kinase C decreases prostaglandin-induced breakdown of the blood-retinal barrier
    • Saishin Y, Saishin Y, Takahashi K, Melia M, Vinores SA, Campochiaro PA. Inhibition of protein kinase C decreases prostaglandin-induced breakdown of the blood-retinal barrier. J Cell Physiol. 2003;195(2):210-219.
    • (2003) J Cell Physiol. , vol.195 , Issue.2 , pp. 210-219
    • Saishin, Y.1    Saishin, Y.2    Takahashi, K.3    Melia, M.4    Vinores, S.A.5    Campochiaro, P.A.6
  • 41
    • 0036168483 scopus 로고    scopus 로고
    • Inducible expression of vascular endothelial growth factor in photoreceptors of adult mice causes severe proliferative retinopathy and retinal detachment
    • Ohno-Matsui K, et al. Inducible expression of vascular endothelial growth factor in photoreceptors of adult mice causes severe proliferative retinopathy and retinal detachment. Am J Pathol. 2002;160(2):711-719.
    • (2002) Am J Pathol. , vol.160 , Issue.2 , pp. 711-719
    • Ohno-Matsui, K.1
  • 42
    • 2342440066 scopus 로고    scopus 로고
    • Functional significance of Tie2 signaling in the adult vasculature
    • Peters KG, et al. Functional significance of Tie2 signaling in the adult vasculature. Recent Prog Horm Res. 2004;59:51-71.
    • (2004) Recent Prog Horm Res. , vol.59 , pp. 51-71
    • Peters, K.G.1
  • 43
    • 60749096085 scopus 로고    scopus 로고
    • Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system
    • Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol. 2009;10(3):165-177.
    • (2009) Nat Rev Mol Cell Biol. , vol.10 , Issue.3 , pp. 165-177
    • Augustin, H.G.1    Koh, G.Y.2    Thurston, G.3    Alitalo, K.4
  • 45
    • 0344874751 scopus 로고    scopus 로고
    • Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1
    • Kelly BD, et al. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res. 2003;93(11):1074-1081.
    • (2003) Circ Res. , vol.93 , Issue.11 , pp. 1074-1081
    • Kelly, B.D.1
  • 46
    • 0037143737 scopus 로고    scopus 로고
    • Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo
    • Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci U S A. 2002;99(17):11205-11210.
    • (2002) Proc Natl Acad Sci U S A , vol.99 , Issue.17 , pp. 11205-11210
    • Lobov, I.B.1    Brooks, P.C.2    Lang, R.A.3
  • 47
    • 2342526664 scopus 로고    scopus 로고
    • Angiopoietin-2 enhances retinal vessel sensitivity to vascular endothelial growth factor
    • Oshima Y, et al. Angiopoietin-2 enhances retinal vessel sensitivity to vascular endothelial growth factor. J Cell Physiol. 2004;199(3):412-417.
    • (2004) J Cell Physiol. , vol.199 , Issue.3 , pp. 412-417
    • Oshima, Y.1
  • 48
    • 0033168876 scopus 로고    scopus 로고
    • Extracellular matrix-integrin binding modulates secretion of angiogenic growth factors by retinal pigmented epithelial cells
    • Mousa SA, Lorelli W, Campochiaro PA. Extracellular matrix-integrin binding modulates secretion of angiogenic growth factors by retinal pigmented epithelial cells. J Cell Biochem. 1999;74(1):135-143.
    • (1999) J Cell Biochem. , vol.74 , Issue.1 , pp. 135-143
    • Mousa, S.A.1    Lorelli, W.2    Campochiaro, P.A.3
  • 49
    • 31944433624 scopus 로고    scopus 로고
    • Implication of the hypoxia response element of the VEGF promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development
    • Vinores SA, et al. Implication of the hypoxia response element of the VEGF promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development. J Cell Physiol. 2006;206(3):749-758.
    • (2006) J Cell Physiol. , vol.206 , Issue.3 , pp. 749-758
    • Vinores, S.A.1
  • 50
    • 64649084437 scopus 로고    scopus 로고
    • Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium
    • Yuan HT, Khankin EV, Karumanchi SA, Parikh SM. Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol. 2009;29(8):2011-2022.
    • (2009) Mol Cell Biol. , vol.29 , Issue.8 , pp. 2011-2022
    • Yuan, H.T.1    Khankin, E.V.2    Karumanchi, S.A.3    Parikh, S.M.4
  • 51
    • 9644279384 scopus 로고    scopus 로고
    • Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor tie-2 in diabetic retinopathy: Effects of laser photocoagulation and angiotensin receptor blockade
    • Lip PL, et al. Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor tie-2 in diabetic retinopathy: effects of laser photocoagulation and angiotensin receptor blockade. Br J Ophthalmol. 2004;88(12):1543-1546.
    • (2004) Br J Ophthalmol. , vol.88 , Issue.12 , pp. 1543-1546
    • Lip, P.L.1
  • 52
    • 69249213967 scopus 로고    scopus 로고
    • Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor
    • Miki K, Miki A, Matsuoka M, Muramatsu D, Hackett SF, Campochiaro PA. Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor. Ophthalmology. 2009;116(9):1748-1754.
    • (2009) Ophthalmology , vol.116 , Issue.9 , pp. 1748-1754
    • Miki, K.1    Miki, A.2    Matsuoka, M.3    Muramatsu, D.4    Hackett, S.F.5    Campochiaro, P.A.6
  • 53
  • 54
    • 58149291905 scopus 로고    scopus 로고
    • VE-PTP maintains the endothelial barrier via plakoglobin and becomes dissociated from VE-cadherin by leukocytes and by VEGF
    • Nottebaum AF, et al. VE-PTP maintains the endothelial barrier via plakoglobin and becomes dissociated from VE-cadherin by leukocytes and by VEGF. J Exp Med. 2008;205(12):2929-2945.
    • (2008) J Exp Med. , vol.205 , Issue.12 , pp. 2929-2945
    • Nottebaum, A.F.1
  • 55
    • 84855493801 scopus 로고    scopus 로고
    • Dissociation of VE-PTP from VE-cadherin is required for leukocyte extravasation and for VEGF-induced vascular permeability in vivo
    • Broermann A, et al. Dissociation of VE-PTP from VE-cadherin is required for leukocyte extravasation and for VEGF-induced vascular permeability in vivo. J Exp Med. 2011;208(12):2393-2401.
    • (2011) J Exp Med. , vol.208 , Issue.12 , pp. 2393-2401
    • Broermann, A.1
  • 56
    • 84883174690 scopus 로고    scopus 로고
    • Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression
    • Goel S, et al. Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression. J Natl Cancer Inst. 2013;105(16):1188-1201.
    • (2013) J Natl Cancer Inst. , vol.105 , Issue.16 , pp. 1188-1201
    • Goel, S.1
  • 57
    • 84860261133 scopus 로고    scopus 로고
    • Skeletal muscle-specific genetic determinants contribute to the differential strain-dependent effects of hindlimb ischemia in mice
    • McClung JM, et al. Skeletal muscle-specific genetic determinants contribute to the differential strain-dependent effects of hindlimb ischemia in mice. Am J Pathol. 2012;180(5):2156-2169.
    • (2012) Am J Pathol. , vol.180 , Issue.5 , pp. 2156-2169
    • McClung, J.M.1
  • 58
    • 0037200045 scopus 로고    scopus 로고
    • Deletion of the carboxyl terminus of Tie2 enhances kinase activity, signaling, and function. Evidence for an autoinhibitory mechanism
    • Niu XL, Peters KG, Kontos CD. Deletion of the carboxyl terminus of Tie2 enhances kinase activity, signaling, and function. Evidence for an autoinhibitory mechanism. J Biol Chem. 2002;277(35):31768-31773.
    • (2002) J Biol Chem. , vol.277 , Issue.35 , pp. 31768-31773
    • Niu, X.L.1    Peters, K.G.2    Kontos, C.D.3
  • 59
    • 0028910237 scopus 로고
    • Maintenance of vascular endothelial cell-specific properties after immortalization with an amphotrophic replication-deficient retrovirus containing human papilloma virus 16 E6/E7 DNA
    • Fontijn R, et al. Maintenance of vascular endothelial cell-specific properties after immortalization with an amphotrophic replication-deficient retrovirus containing human papilloma virus 16 E6/E7 DNA. Exp. Cell Res. 1995;216(1):199-201.
    • (1995) Exp. Cell Res. , vol.216 , Issue.1 , pp. 199-201
    • Fontijn, R.1
  • 60
    • 77953515701 scopus 로고    scopus 로고
    • Digoxin inhibits retinal ischemia-induced HIF-1alpha expression and ocular neovascularization
    • Yoshida T, Zhang H, Iwase T, Shen J, Semenza GL, Campochiaro PA. Digoxin inhibits retinal ischemia-induced HIF-1alpha expression and ocular neovascularization. FASEB J. 2010;24(6):1759-1767.
    • (2010) FASEB J. , vol.24 , Issue.6 , pp. 1759-1767
    • Yoshida, T.1    Zhang, H.2    Iwase, T.3    Shen, J.4    Semenza, G.L.5    Campochiaro, P.A.6
  • 61
    • 80052278961 scopus 로고    scopus 로고
    • Vascular cell adhesion molecule-1 plays a central role in the proangiogenic effects of oxidative stress
    • Dong A, Shen J, Zeng M, Campochiaro PA. Vascular cell adhesion molecule-1 plays a central role in the proangiogenic effects of oxidative stress. Proc Natl Acad Sci U S A. 2011;108(35):14614-14619.
    • (2011) Proc Natl Acad Sci U S A , vol.108 , Issue.35 , pp. 14614-14619
    • Dong, A.1    Shen, J.2    Zeng, M.3    Campochiaro, P.A.4
  • 62
    • 39149139617 scopus 로고    scopus 로고
    • Structurally distinct phosphatases CD45 and CD148 both regulate B cell and macrophage immunoreceptor signaling
    • Zhu JW, Brdicka T, Katsumoto TR, Lin J, Weiss A. Structurally distinct phosphatases CD45 and CD148 both regulate B cell and macrophage immunoreceptor signaling. Immunity. 2008;28(2):183-196.
    • (2008) Immunity , vol.28 , Issue.2 , pp. 183-196
    • Zhu, J.W.1    Brdicka, T.2    Katsumoto, T.R.3    Lin, J.4    Weiss, A.5
  • 64
    • 77957738254 scopus 로고    scopus 로고
    • Agents that bind annexin A2 suppress ocular neovascularization
    • Lima E Silva R, et al. Agents that bind annexin A2 suppress ocular neovascularization. J Cell Physiol. 2010;225(3):855-864.
    • (2010) J Cell Physiol. , vol.225 , Issue.3 , pp. 855-864
    • Silva, L.E.R.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.